LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP - News) (the “Company” or “Lightlake”), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it is seeking to collaborate with Europe’s largest centre for research and post-graduate education in psychiatry, King’s College London Institute of Psychiatry, to develop a new treatment for opiate overdose.
